B-intervention	0	11	Rivaroxaban
O	12	20	compared
O	21	23	to
B-control	24	26	no
I-control	27	36	treatment
O	37	39	in
O	40	42	ER
O	42	43	-
O	43	51	negative
O	52	57	stage
O	58	59	I
O	59	60	-
O	60	63	III
O	64	69	early
O	70	76	breast
O	77	83	cancer
O	84	92	patients
O	93	94	(
O	94	97	the
O	98	101	TIP
O	102	107	Trial
O	107	108	)
O	108	109	:
O	110	115	study
O	116	124	protocol
O	125	128	for
O	129	130	a
O	131	136	phase
O	137	139	II
O	140	152	preoperative
O	153	159	window
O	159	160	-
O	160	162	of
O	162	163	-
O	163	174	opportunity
O	175	180	study
O	181	187	design
O	188	198	randomised
O	199	209	controlled
O	210	215	trial
O	215	216	.

O	217	223	Breast
O	224	230	cancer
O	231	239	patients
O	240	243	are
O	244	246	at
O	247	248	a
O	249	253	four
O	253	254	-
O	254	258	fold
O	259	268	increased
O	269	273	risk
O	274	276	of
O	277	287	developing
O	288	289	a
O	290	296	venous
O	297	312	thromboembolism
O	313	314	(
O	314	317	VTE
O	317	318	)
O	318	319	,
O	320	321	a
O	322	327	major
O	328	333	cause
O	334	336	of
O	337	342	death
O	343	345	in
O	346	350	this
O	351	356	group
O	356	357	.

O	358	368	Conversely
O	368	369	,
O	370	381	coagulation
O	382	389	factors
O	390	397	promote
O	398	404	tumour
O	405	411	growth
O	412	415	and
O	416	426	metastasis
O	426	427	.

O	428	432	This
O	433	436	has
O	437	441	been
O	442	451	evidenced
O	452	454	in
O	455	466	preclinical
O	467	473	models
O	473	474	,
O	475	479	with
O	480	482	an
O	483	493	inhibitory
O	494	500	effect
O	501	503	of
O	504	518	anticoagulants
O	519	521	on
O	522	528	cancer
O	529	535	growth
O	536	543	through
O	544	557	proliferative
O	557	558	,
O	559	569	angiogenic
O	569	570	,
O	571	580	apoptotic
O	580	581	,
O	582	588	cancer
O	589	593	stem
O	594	598	cell
O	599	602	and
O	603	613	metastatic
O	614	623	processes
O	623	624	.

O	625	628	The
O	629	638	extrinsic
O	639	647	clotting
O	648	655	pathway
O	656	658	is
O	659	663	also
O	664	668	more
O	669	680	upregulated
O	681	683	in
O	684	692	patients
O	693	695	in
O	696	699	the
O	700	710	relatively
O	711	717	poorer
O	718	727	prognosis
O	728	737	oestrogen
O	738	746	receptor
O	747	748	(
O	748	750	ER
O	750	751	)
O	751	752	-
O	752	760	negative
O	761	767	breast
O	768	774	cancer
O	775	783	subgroup
O	783	784	,
O	785	789	with
O	790	799	increased
O	800	806	tumour
O	807	814	stromal
O	815	825	expression
O	826	828	of
O	829	832	the
O	833	844	coagulation
O	845	852	factors
O	853	859	Tissue
O	860	866	Factor
O	867	870	and
O	871	879	thrombin
O	879	880	.

O	881	892	Rivaroxaban
O	893	894	(
O	894	901	Xarelto
O	901	902	®
O	902	903	,
O	904	909	Bayer
O	910	912	AG
O	912	913	,
O	914	924	Leverkusen
O	924	925	,
O	926	933	Germany
O	933	934	)
O	935	937	is
O	938	939	a
O	940	946	direct
O	947	951	oral
O	952	965	anticoagulant
O	966	967	(
O	967	971	DOAC
O	971	972	)
O	972	973	.

O	974	976	It
O	977	979	is
O	980	981	a
O	982	988	Factor
O	989	991	Xa
O	992	1001	inhibitor
O	1002	1006	that
O	1007	1009	is
O	1010	1019	routinely
O	1020	1030	prescribed
O	1031	1034	for
O	1035	1038	the
O	1039	1049	prevention
O	1050	1052	of
O	1053	1059	stroke
O	1060	1062	in
O	1063	1066	non
O	1066	1067	-
O	1067	1075	valvular
O	1076	1082	atrial
O	1083	1095	fibrillation
O	1096	1099	and
O	1100	1103	for
O	1104	1108	both
O	1109	1112	VTE
O	1113	1124	prophylaxis
O	1125	1128	and
O	1129	1138	treatment
O	1138	1139	.

O	1140	1144	This
O	1145	1150	trial
O	1151	1155	will
O	1156	1162	assess
O	1163	1166	the
O	1167	1171	anti
O	1171	1172	-
O	1172	1185	proliferative
O	1186	1189	and
O	1190	1195	other
O	1196	1200	anti
O	1200	1201	-
O	1201	1207	cancer
O	1208	1219	progression
O	1220	1230	mechanisms
O	1231	1233	of
O	1234	1245	Rivaroxaban
O	1246	1248	in
O	1249	1251	ER
O	1251	1252	-
O	1252	1260	negative
O	1261	1266	early
O	1267	1273	breast
O	1274	1280	cancer
O	1281	1289	patients
O	1289	1290	.

O	1291	1295	This
B-location	1296	1298	UK
O	1298	1299	-
O	1299	1304	based
O	1305	1317	preoperative
O	1318	1324	window
O	1324	1325	-
O	1325	1327	of
O	1327	1328	-
O	1328	1339	opportunity
O	1340	1345	phase
O	1346	1348	II
O	1349	1359	randomised
O	1360	1367	control
O	1368	1373	trial
O	1374	1378	will
O	1379	1388	randomise
B-total-participants	1389	1391	88
B-eligibility	1392	1401	treatment
I-eligibility	1401	1402	-
I-eligibility	1402	1404	na
I-eligibility	1404	1405	ï
I-eligibility	1405	1407	ve
I-eligibility	1408	1413	early
I-eligibility	1414	1420	breast
I-eligibility	1421	1427	cancer
I-eligibility	1428	1436	patients
O	1437	1439	to
O	1440	1447	receive
O	1448	1450	20
O	1451	1453	mg
O	1454	1456	OD
O	1457	1468	Rivaroxaban
O	1469	1478	treatment
O	1479	1482	for
O	1483	1485	11
O	1486	1488	to
O	1489	1491	17
O	1492	1496	days
O	1497	1499	or
O	1500	1502	no
O	1503	1512	treatment
O	1512	1513	.

O	1514	1523	Treatment
O	1524	1528	will
O	1529	1531	be
O	1532	1539	stopped
O	1540	1542	24
O	1543	1544	h
O	1545	1546	(
O	1546	1551	range
O	1552	1554	18
O	1554	1555	-
O	1555	1557	36
O	1558	1559	h
O	1559	1560	)
O	1561	1566	prior
O	1567	1569	to
O	1570	1577	surgery
O	1578	1580	or
O	1581	1587	repeat
O	1588	1592	core
O	1593	1599	biopsy
O	1599	1600	.

O	1601	1604	All
O	1605	1613	patients
O	1614	1618	will
O	1619	1621	be
O	1622	1630	followed
O	1631	1633	up
O	1634	1637	for
O	1638	1639	2
O	1640	1645	weeks
O	1646	1655	following
O	1656	1663	surgery
O	1664	1666	or
O	1667	1673	repeat
O	1674	1678	core
O	1679	1685	biopsy
O	1685	1686	.

O	1687	1690	The
O	1691	1698	primary
O	1699	1707	endpoint
O	1708	1710	is
B-outcome-Measure	1711	1717	change
I-outcome-Measure	1718	1720	in
I-outcome-Measure	1721	1727	tumour
I-outcome-Measure	1728	1732	Ki67
O	1732	1733	.

O	1734	1743	Secondary
O	1744	1751	outcome
O	1752	1760	measures
O	1761	1768	include
B-outcome-Measure	1769	1775	tumour
I-outcome-Measure	1776	1783	markers
I-outcome-Measure	1784	1786	of
I-outcome-Measure	1787	1796	apoptosis
I-outcome-Measure	1797	1800	and
I-outcome-Measure	1801	1813	angiogenesis
I-outcome-Measure	1813	1814	,
I-outcome-Measure	1815	1824	extrinsic
I-outcome-Measure	1825	1833	clotting
I-outcome-Measure	1834	1841	pathway
I-outcome-Measure	1842	1852	activation
I-outcome-Measure	1853	1856	and
I-outcome-Measure	1857	1865	systemic
I-outcome-Measure	1866	1873	markers
I-outcome-Measure	1874	1876	of
I-outcome-Measure	1877	1887	metastasis
I-outcome-Measure	1887	1888	,
I-outcome-Measure	1889	1895	tumour
I-outcome-Measure	1896	1900	load
I-outcome-Measure	1901	1904	and
I-outcome-Measure	1905	1916	coagulation
O	1916	1917	.

O	1918	1928	Laboratory
O	1929	1937	evidence
O	1938	1946	supports
O	1947	1949	an
O	1950	1954	anti
O	1954	1955	-
O	1955	1961	cancer
O	1962	1966	role
O	1967	1970	for
O	1971	1985	anticoagulants
O	1985	1986	;
O	1987	1994	however
O	1994	1995	,
O	1996	2000	this
O	2001	2004	has
O	2005	2011	failed
O	2012	2014	to
O	2015	2024	translate
O	2025	2029	into
B-outcome	2030	2038	survival
I-outcome	2039	2046	benefit
O	2047	2051	when
O	2052	2060	trialled
O	2061	2063	in
O	2064	2072	patients
O	2073	2077	with
O	2078	2088	metastatic
O	2089	2096	disease
O	2097	2099	or
O	2100	2104	poor
O	2105	2114	prognosis
O	2115	2122	cancers
O	2122	2123	,
O	2124	2128	such
O	2129	2131	as
O	2132	2136	lung
O	2137	2143	cancer
O	2143	2144	.

O	2145	2153	Subgroup
O	2154	2162	analysis
O	2163	2172	supported
O	2173	2174	a
B-outcome	2175	2184	potential
I-outcome	2185	2193	survival
I-outcome	2194	2201	benefit
O	2202	2204	in
O	2205	2211	better
O	2212	2221	prognosis
O	2222	2230	advanced
O	2231	2238	disease
O	2239	2247	patients
O	2247	2248	.

O	2249	2253	This
O	2254	2256	is
O	2257	2260	the
O	2261	2266	first
O	2267	2272	study
O	2273	2275	to
O	2276	2287	investigate
O	2288	2291	the
O	2292	2296	anti
O	2296	2297	-
O	2297	2303	cancer
O	2304	2311	effects
O	2312	2314	of
O	2315	2329	anticoagulants
O	2330	2332	in
O	2333	2338	early
O	2339	2345	breast
O	2346	2352	cancer
O	2352	2353	.

O	2354	2356	UK
O	2357	2365	National
O	2366	2374	Research
O	2375	2381	Ethics
O	2382	2389	Service
O	2390	2391	(
O	2391	2395	NRES
O	2395	2396	)
O	2397	2405	approval
O	2406	2408	15
O	2408	2409	/
O	2409	2411	NW
O	2411	2412	/
O	2412	2416	0406
O	2416	2417	,
O	2418	2422	MHRA
O	2423	2431	Clinical
O	2432	2438	Trials
O	2439	2452	Authorisation
O	2453	2458	48380
O	2458	2459	/
O	2459	2463	0003
O	2463	2464	/
O	2464	2467	001
O	2467	2468	-
O	2468	2472	0001
O	2472	2473	.

O	2474	2477	The
O	2478	2485	sponsor
O	2486	2488	is
O	2489	2499	Manchester
O	2500	2510	University
O	2511	2514	NHS
O	2515	2525	Foundation
O	2526	2531	Trust
O	2531	2532	,
O	2533	2536	and
O	2537	2540	the
O	2541	2546	trial
O	2547	2549	is
O	2550	2552	co
O	2552	2553	-
O	2553	2562	ordinated
O	2563	2565	by
O	2566	2572	Cancer
O	2573	2581	Research
O	2582	2584	UK
O	2585	2594	Liverpool
O	2595	2601	Cancer
O	2602	2608	Trials
O	2609	2613	Unit
O	2614	2615	(
O	2615	2619	LCTU
O	2619	2620	)
O	2620	2621	.

O	2622	2629	EudraCT
O	2630	2634	2014
O	2634	2635	-
O	2635	2641	004909
O	2641	2642	-
O	2642	2644	33
O	2645	2646	,
O	2647	2657	registered
O	2658	2660	27
O	2661	2665	July
O	2666	2670	2015
O	2670	2671	.

O	2672	2686	ISRCTN14785273
O	2687	2688	.
